Duggan Megan相关文献与解析，生知库 | 链接生命科学的每一步

Savardekar, Himanshu; Stiff, Andrew; Liu, Alvin; Wesolowski, Robert; Schwarz, Emily; Garbarine, Ian C; Duggan, Megan C; Zelinskas, Sara; Li, Jianying; Lapurga, Gabriella; Abreo, Alexander; Savardekar, Lohith; Parker, Ryan; Sabella, Julia; DiVincenzo, Mallory J; Benner, Brooke; Sun, Steven H; Quiroga, Dionisia; Scarberry, Luke; Xin, Gang; Dey, Anup; Ozato, Keiko; Yu, Lianbo; Hasanov, Merve; Sundi, Debasish; Wu, Richard C; Kendra, Kari L; Carson, William E 3rd

MDSC

凋亡

表观遗传

A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade

比较接受免疫检查点阻断治疗的溃疡性黑色素瘤患者和非溃疡性黑色素瘤患者髓系来源抑制细胞群

期刊:Melanoma Research

影响因子:1.9

doi:10.1097/CMR.0000000000001023

Angell, Colin D; Sun, Steven H; Lapurga, Gabriella; Benner, Brooke; Quiroga, Dionisia; Savardekar, Himanshu; DiVincenzo, Mallory J; Abood, David; Stiff, Andrew; Duggan, Megan; Handley, Demond; Nagle, Erin; Howard, J Harrison; Shah, Hiral; Kendra, Kari L; Carson, William E 3rd

Looking after each other in a crisis-Lessons from Novichok and the parallels with Covid-19

危机中互帮互助——诺维乔克事件的教训及其与新冠肺炎的相似之处

期刊:Nursing in Critical Care

影响因子:2.6

doi:10.1111/nicc.12677

Jenkins, Kate S M; Thomas, Jess; Duggan, Megan; Scott, Hannah; Lang, Jenny

Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

对接受新辅助化疗的可手术乳腺癌患者循环T细胞和肿瘤标本中免疫检查点受体表达进行探索性分析

期刊:BMC Cancer

影响因子:3.4

doi:10.1186/s12885-020-06949-4

Wesolowski, Robert; Stiff, Andrew; Quiroga, Dionisia; McQuinn, Christopher; Li, Zaibo; Nitta, Hiroaki; Savardekar, Himanshu; Benner, Brooke; Ramaswamy, Bhuvaneswari; Lustberg, Maryam; Layman, Rachel M; Macrae, Erin; Kassem, Mahmoud; Williams, Nicole; Sardesai, Sagar; VanDeusen, Jeffrey; Stover, Daniel; Cherian, Mathew; Mace, Thomas A; Yu, Lianbo; Duggan, Megan; Carson, William E 3rd

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma

一项针对无法切除的原发性或复发性头颈部鳞状细胞癌患者的西妥昔单抗联合白细胞介素-12治疗的I/II期临床试验

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-18-2108

McMichael, Elizabeth L; Benner, Brooke; Atwal, Lakhvir S; Courtney, Nicholas B; Mo, Xiaokui; Davis, Melanie E; Campbell, Amanda R; Duggan, Megan C; Williams, Kallan; Martin, Kyle; Levine, Kala; Olaverria Salavaggione, Gonzalo N; Noel, Tiffany; Ganju, Akaansha; Uppati, Sarvani; Paul, Bonnie; Olencki, Thomas; Teknos, Theodoros N; Savvides, Panos; Tridandapani, Susheela; Byrd, John C; Caligiuri, Michael A; Liu, Stephen V; Carson, William E 3rd

An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.

基于 IL-15 的超激动剂 ALT-803 可增强 NK 细胞对西妥昔单抗治疗的头颈部鳞状细胞癌的反应

期刊:Cancer Immunology Immunotherapy

影响因子:5.1

doi:10.1007/s00262-019-02372-2

Pinette Ashley, McMichael Elizabeth, Courtney Nicholas B, Duggan Megan, Benner Brooke N, Choueiry Fouad, Yu Lianbo, Abood David, Mace Thomas A, Carson William E 3rd

Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes

基于基因表达和网络挖掘的协同作用（SynGeNet）方法预测不同黑色素瘤基因组亚型的协同药物组合

期刊:npj Systems Biology and Applications

影响因子:3.5

doi:10.1038/s41540-019-0085-4

Regan-Fendt, Kelly E; Xu, Jielin; DiVincenzo, Mallory; Duggan, Megan C; Shakya, Reena; Na, Ryejung; Carson, William E 3rd; Payne, Philip R O; Li, Fuhai

黑色素瘤

发表日期：2019

文献求助收藏

Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors

采用BET和免疫检查点抑制剂联合治疗乳腺癌的模型

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.1721559115

Lai, Xiulan; Stiff, Andrew; Duggan, Megan; Wesolowski, Robert; Carson, William E 3rd; Friedman, Avner

Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma

对 MLN4924（培沃地司他）作为恶性黑色素瘤潜在治疗药物的分析

期刊:Melanoma Research

影响因子:1.9

doi:10.1097/CMR.0000000000000474

Olaverria Salavaggione, Gonzalo N; Duggan, Megan C; Carson, William E

黑色素瘤

发表日期：2018

文献求助收藏

BRD4 inhibition leads to MDSC apoptosis and enhances checkpoint blockade therapy

BRD4抑制可导致MDSC凋亡并增强免疫检查点阻断疗法的效果。

A comparison of myeloid-derived suppressor cell populations in patients with ulcerated vs non-ulcerated melanoma receiving immune checkpoint blockade

比较接受免疫检查点阻断治疗的溃疡性黑色素瘤患者和非溃疡性黑色素瘤患者髓系来源抑制细胞群

Looking after each other in a crisis-Lessons from Novichok and the parallels with Covid-19

危机中互帮互助——诺维乔克事件的教训及其与新冠肺炎的相似之处

Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer

对接受新辅助化疗的可手术乳腺癌患者循环T细胞和肿瘤标本中免疫检查点受体表达进行探索性分析

A Phase I/II Trial of Cetuximab in Combination with Interleukin-12 Administered to Patients with Unresectable Primary or Recurrent Head and Neck Squamous Cell Carcinoma

一项针对无法切除的原发性或复发性头颈部鳞状细胞癌患者的西妥昔单抗联合白细胞介素-12治疗的I/II期临床试验

An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck.

基于 IL-15 的超激动剂 ALT-803 可增强 NK 细胞对西妥昔单抗治疗的头颈部鳞状细胞癌的反应

Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes

基于基因表达和网络挖掘的协同作用（SynGeNet）方法预测不同黑色素瘤基因组亚型的协同药物组合

Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors

采用BET和免疫检查点抑制剂联合治疗乳腺癌的模型

Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma

对 MLN4924（培沃地司他）作为恶性黑色素瘤潜在治疗药物的分析